Effects of L-dopa and bromocriptine on calcitonin secretion in medullary thyroid carcinoma.
The secretion of calcitonin (CT) by thyroid C cells has been reported to be reduced by dopamine in vitro and by L-dopa in patients with medullary thyroid carcinoma (MTC). These results have suggested that dopa uptake ad decarboxylation to dopamine may play an inhibitory role in the control of CT secretion. We studied the effects of either L-dopa or bromocriptine, a dopamine agonist, on CT secretion in 11 patients with MTC. Seven patients had multiple endocrine adenomatosis type II (MEA II), 1 had MEA III, and 3 had sporadic MTC. Metastatic disease was confirmed in 8, was probable in 2, and was absent in 1. L-Dopa (500 mg orally) was given to 10 patients in 12 trials. Serum obtained serially for CT measurement RIA over a 4-h period showed a fall in 4 instances in 3 patients; there was no decrease in 7 patients. Absorption of L-dopa was confirmed by the finding of the expected rise in serum GH concentration in all nonresponders except 1. Bromocriptine administered in increasing doses (7.5-50 mg/day) for periods from 4-18 weeks in 5 patients with metastatic disease failed to lower the serum CT concentration in any patient. In 2 of 4 cases, pentagastrin-induced CT release was augmented during bromocriptine administration. These results show L-dopa suppression of CT secretion only in a minority of patients with MTC; the lack of response to bromocriptine suggessts that dopamine receptor stimulation by dopaminergic ergots does not inhibit CT secretion in this same group of patients.
D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000494:pharmacology*; D002116:Calcitonin / Q000378:metabolism*; D002277:Carcinoma / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin; D013964:Thyroid Neoplasms / Q000378:metabolism*
D001971:Bromocriptine; D007980:Levodopa; D002116:Calcitonin; D010418:Pentagastrin